Recently, PR has been reported to be highly expressed and an independent negative prognostic factor for clinical trials for prostate cancer [22] thereby making inhibition of PR a potential benefit of an approach that blocks both AR NTD and PR. The gene discussed is PGR; the disease is Familial prostate cancer.